FCB Pharmicell Co., Ltd.
Records under this name other than patents FCB Pharmicell Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 4 of 4 · Back to FCB Pharmicell Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,229,827 | Method for differentiating mesenchymal stem cells into neural cells Formerly held Term ended Term ended Jan 16, 2024 · From the USPTO record | Term ended | Term ended Jan 16, 2024 | From the USPTO record |
| US 7,390,658 | CD8α+lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation Formerly held Term ended Term ended Jul 26, 2022 · From the USPTO record | Term ended | Term ended Jul 26, 2022 | From the USPTO record |
| US 7,635,591 | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease Formerly held Lapsed on the fee record Ended Dec 22, 2017 · From the USPTO record | Lapsed on the fee record | Ended Dec 22, 2017 | From the USPTO record |
| US 7,390,800 | Adenosine deaminase inhibitor and novel Bacillus sp. Iada-7 strain which produces it Formerly held Lapsed on the fee record Ended Jun 24, 2016 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2016 | From the USPTO record |